249 related articles for article (PubMed ID: 31847908)
1. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
[TBL] [Abstract][Full Text] [Related]
2. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
[TBL] [Abstract][Full Text] [Related]
3. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
[TBL] [Abstract][Full Text] [Related]
6. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
[TBL] [Abstract][Full Text] [Related]
7. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
9. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
10. Topical Tacrolimus 0.1% for treatment of cutaneous microcystic lymphatic malformations.
Salvia SA; Amore MA; Papendieck CM
Lymphology; 2021; 54(2):106-111. PubMed ID: 34735755
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
Wiegand S; Wichmann G; Dietz A
Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.
Ricci KW; Hammill AM; Mobberley-Schuman P; Nelson SC; Blatt J; Bender JLG; McCuaig CC; Synakiewicz A; Frieden IJ; Adams DM
Pediatr Blood Cancer; 2019 May; 66(5):e27614. PubMed ID: 30672136
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review.
Teng JMC; Hammill A; Martini J; Treat J
Lymphat Res Biol; 2023 Apr; 21(2):101-110. PubMed ID: 35852876
[No Abstract] [Full Text] [Related]
16. Efficacy of Topical Sirolimus (Rapamycin) for the Treatment of Microcystic Lymphatic Malformations.
Ivars M; Redondo P
JAMA Dermatol; 2017 Jan; 153(1):103-105. PubMed ID: 27784048
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial.
Redl A; Doberer K; Unterluggauer L; Kleissl L; Krall C; Mayerhofer C; Reininger B; Stary V; Zila N; Weninger W; Weichhart T; Bock C; Krausgruber T; Stary G
Lancet Rheumatol; 2024 Feb; 6(2):e81-e91. PubMed ID: 38267106
[TBL] [Abstract][Full Text] [Related]
18. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
[No Abstract] [Full Text] [Related]
19. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial.
Wilken R; Li CS; Sharon VR; Kim K; Patel FB; Patel F; Maverakis E
Trials; 2015 Aug; 16():374. PubMed ID: 26297574
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).
Ozeki M; Asada R; Saito AM; Hashimoto H; Fujimura T; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Yamada Y; Fujino A; Hirakawa S; Furukawa T; Tajiri T; Kinoshita Y; Souzaki R; Fukao T
Regen Ther; 2019 Jun; 10():84-91. PubMed ID: 30705924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
